330 related articles for article (PubMed ID: 30844945)
1. Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics.
Thomas AS
Curr Opin Ophthalmol; 2019 May; 30(3):138-150. PubMed ID: 30844945
[TBL] [Abstract][Full Text] [Related]
2. Current Knowledge of Biologics in Treatment of Noninfectious Uveitis.
Gupta S; Shyamsundar K; Agrawal M; Vichare N; Biswas J
J Ocul Pharmacol Ther; 2022 Apr; 38(3):203-222. PubMed ID: 35133890
[TBL] [Abstract][Full Text] [Related]
3. Biologic therapy for Behçet's uveitis: a systematic review.
Uke P; Gorodkin R; Beare N
Br J Ophthalmol; 2020 Aug; 104(8):1045-1051. PubMed ID: 31676596
[TBL] [Abstract][Full Text] [Related]
4. Local treatment of infectious and noninfectious intermediate, posterior, and panuveitis: current concepts and emerging therapeutics.
Thomas AS; Lin P
Curr Opin Ophthalmol; 2020 May; 31(3):174-184. PubMed ID: 32168001
[TBL] [Abstract][Full Text] [Related]
5. Advancements in the management of uveitis.
Schwartzman S
Best Pract Res Clin Rheumatol; 2016 Apr; 30(2):304-315. PubMed ID: 27886802
[TBL] [Abstract][Full Text] [Related]
6. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.
Levy-Clarke G; Jabs DA; Read RW; Rosenbaum JT; Vitale A; Van Gelder RN
Ophthalmology; 2014 Mar; 121(3):785-96.e3. PubMed ID: 24359625
[TBL] [Abstract][Full Text] [Related]
7. Lower Relapses Rate With Infliximab Versus Adalimumab in Sight-Threatening Uveitis: A Multicenter Study of 330 Patients.
Maalouf G; Andrillon A; Leclercq M; Sève P; Bielefeld P; Gueudry J; Sené T; Titah C; Moulinet T; Rouvière B; Sène D; Desbois AC; Domont F; Touhami S; Thibault T; Chamieh CE; Cacoub P; Kodjikian L; Biard L; Bodaghi B; Saadoun D
Am J Ophthalmol; 2022 Jun; 238():173-180. PubMed ID: 35172172
[TBL] [Abstract][Full Text] [Related]
8. Biologics in the Treatment of Uveitis.
Dingerkus VLS; Becker MD; Doycheva D
Klin Monbl Augenheilkd; 2022 May; 239(5):686-694. PubMed ID: 35426112
[TBL] [Abstract][Full Text] [Related]
9. The current status of biological treatment for uveitis.
Gaggiano C; Sota J; Gentileschi S; Caggiano V; Grosso S; Tosi GM; Frediani B; Cantarini L; Fabiani C
Expert Rev Clin Immunol; 2020 Aug; 16(8):787-811. PubMed ID: 32700605
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Outcomes of Treatment with Biological Agents in Eyes with Refractory, Active, Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis.
Al-Janabi A; El Nokrashy A; Sharief L; Nagendran V; Lightman S; Tomkins-Netzer O
Ophthalmology; 2020 Mar; 127(3):410-416. PubMed ID: 31607412
[TBL] [Abstract][Full Text] [Related]
11. The effect of anti-tumor necrosis factor alpha agents on the outcome in pediatric uveitis of diverse etiologies.
Deitch I; Amer R; Tomkins-Netzer O; Habot-Wilner Z; Friling R; Neumann R; Kramer M
Graefes Arch Clin Exp Ophthalmol; 2018 Apr; 256(4):801-808. PubMed ID: 29455252
[TBL] [Abstract][Full Text] [Related]
12. Biotherapies in Uveitis.
Leclercq M; Desbois AC; Domont F; Maalouf G; Touhami S; Cacoub P; Bodaghi B; Saadoun D
J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33171664
[TBL] [Abstract][Full Text] [Related]
13. The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behçet's disease: results of a multicentre open-label study.
Santos-Gómez M; Calvo-Río V; Blanco R; Beltrán E; Mesquida M; Adán A; Cordero-Coma M; García-Aparicio ÁM; Valls Pascual E; Martínez-Costa L; Hernández MV; Hernandez Garfella M; González-Vela MC; Pina T; Palmou-Fontana N; Loricera J; Hernández JL; González-Gay MA
Clin Exp Rheumatol; 2016; 34(6 Suppl 102):S34-S40. PubMed ID: 27054359
[TBL] [Abstract][Full Text] [Related]
14. Non-anti TNFα biologic agents for noninfectious uveitis associated with systemic inflammatory diseases: a systematic review.
Bitossi A; Mattioli I; Bettiol A; Palermo A; Malandrino D; Bacherini D; Virgili G; Giansanti F; Vannozzi L; Silvestri E
Expert Rev Clin Immunol; 2023 May; 19(5):549-560. PubMed ID: 36939549
[TBL] [Abstract][Full Text] [Related]
15. Perspectives for immunotherapy in noninfectious immune mediated uveitis.
Touhami S; Gueudry J; Leclercq M; Touitou V; Ghembaza A; Errera MH; Saadoun D; Bodaghi B
Expert Rev Clin Immunol; 2021 Sep; 17(9):977-989. PubMed ID: 34264142
[No Abstract] [Full Text] [Related]
16. Challenges for further successful development of tumor necrosis factor targeting therapies for uveitis.
Thng ZX; Regenold J; Bromeo AJ; Akhavanrezayat A; Than NTT; Khatri A; Mohammadi SS; Tran ANT; Shin YU; Karaca I; Ghoraba HH; Or CCM; Nguyen QD
Expert Opin Investig Drugs; 2024 Feb; 33(2):95-104. PubMed ID: 38299551
[TBL] [Abstract][Full Text] [Related]
17. Comparison of infliximab with adalimumab for the treatment of non-infectious uveitis: a systematic review and meta-analysis.
Liu W; Bai D; Kou L
BMC Ophthalmol; 2023 May; 23(1):240. PubMed ID: 37248486
[TBL] [Abstract][Full Text] [Related]
18. Biologics in the treatment of uveitis.
Imrie FR; Dick AD
Curr Opin Ophthalmol; 2007 Nov; 18(6):481-6. PubMed ID: 18163000
[TBL] [Abstract][Full Text] [Related]
19. Expert opinion on the use of biological therapy in non-infectious uveitis.
Touhami S; Diwo E; Sève P; Trad S; Bielefeld P; Sène D; Abad S; Brézin A; Quartier P; Koné Paut I; Weber M; Chiquet C; Errera MH; Sellam J; Cacoub P; Kaplanski G; Kodjikian L; Bodaghi B; Saadoun D
Expert Opin Biol Ther; 2019 May; 19(5):477-490. PubMed ID: 30888881
[TBL] [Abstract][Full Text] [Related]
20. Antidrug Antibodies to Tumor Necrosis Factor α Inhibitors in Patients With Noninfectious Uveitis.
Bellur S; McHarg M; Kongwattananon W; Vitale S; Sen HN; Kodati S
JAMA Ophthalmol; 2023 Feb; 141(2):150-156. PubMed ID: 36547953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
